Active Energy Group PLC (AIM:AEG, OTCQB:ATGVF) (AEG) said work last year had helped it set the stage for “significant commercial progress for 2023 and beyond”.
The company is at the vanguard of the green energy revolution having pioneered a technology called CoalSwitch, which allows waste wood to be pulped down into pellets that can then be burned by traditional power stations.
Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) has said Leopoldo Zambeletti is relinquishing his independent directorship of the company to take on a senior business development role at the firm.
This strategic move will allow Zambeletti to fully focus on facilitating prospective partnerships for the future plans of bexmarilimab, the company's flagship cancer therapeutic.
Roquefort Therapeutics PLC (LSE:ROQ, OTCQB:ROQAF) said one of its drug development programmes is on course for ‘clinical readiness’ in the second half of this year.
Although the group didn’t say which constituent of its oncology pipeline might make that crucial next step, it was upbeat on the prospects for its portfolio.
ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the developer of the Parsortix liquid biopsy, has enhanced its executive roster with two key appointments: Brett Swansiger as chief commercial officer (CCO) and Karen Miller as chief scientific officer (CSO).
Both bring with them significant industry experience that it is hoped will help the group deliver its "strategic and commercial objectives".
Greatland Gold PLC (AIM:GGP, OTC:GRLGF) has divested its Tasmanian tenements Firetower and Warrentinna to Flynn Gold, which exercised its option over the prospects.
Flynn Gold will pay Greatland A$200,000 in shares at A$0.10, with further payments of A$500,000 due upon completion of a JORC mineral resource and another A$500,000 once a permit to mine is awarded.